Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy

Digestive Diseases and Sciences

Volumn 56, Issue 1, 2011, Pages 131-138

  Jeong, Seong Hyun ^a   Han, Jae Ho ^a   Kim, Jang Hee ^a   Ahn, Mi Sun ^a   Hwang, Yoon Ho ^a   Lee, Hyun Woo ^a   Kang, Seok Yun ^a   Park, Joon Seong ^a   Choi, Jin Hyuk ^a   Lee, Kwang Jae ^a   Sheen, Seung Soo ^a   Lim, Ho Yeong ^b  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bax; Chemotherapy; Gastric cancer; Prognosis

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN BAX; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79151474708     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1280-8     Document Type: Article

References (33)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. I Chau AR Norman D Cunningham, et al. 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395 2403 10.1200/JCO.2004.08.154 15197201
3. F Rivera ME Vega-Villegas MF Lopez-Brea 2007 Chemotherapy of advanced gastric cancer Cancer Treat Rev 33 315 324 1:CAS:528:DC%2BD2sXlsF2rsb0%3D 10.1016/j.ctrv.2007.01.004 17376598
4. E Van Cutsem C Van de Velde A Roth, et al. 2008 Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group Eur J Cancer 44 182 194 10.1016/j.ejca.2007.11.001 18093827
5. AD Wagner W Grothe J Haerting, et al. 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 1:CAS:528:DC%2BD28XntV2gs7s%3D 10.1200/JCO.2005.05.0245 16782930
6. SS Wohrer M Raderer M Hejna 2004 Palliative chemotherapy for advanced gastric cancer Ann Oncol 15 1585 1595 1:STN:280:DC%2BD2crkslSltg%3D%3D 10.1093/annonc/mdh422 15520058
7. SE Al-Batran JT Hartmann S Probst, et al. 2008 Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 1435 1442 1:CAS:528: DC%2BD1cXkslKqsL8%3D 10.1200/JCO.2007.13.9378 18349393
8. D Cunningham N Starling S Rao, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 1:CAS:528: DC%2BD1cXisFSktg%3D%3D 10.1056/NEJMoa073149 18172173
9. F De Vita M Orditura E Matano, et al. 2005 A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients Br J Cancer 92 1644 1649 10.1038/sj.bjc.6602573 15856038
10. C Louvet T Andre JM Tigaud, et al. 2002 Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543 4548 1:CAS:528:DC%2BD38XovVeisLw%3D 10.1200/JCO.2002.02.021 12454110
11. J Lee T Lim JE Uhm, et al. 2007 Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 18 886 891 1:STN:280:DC%2BD2s3ns1Klsg%3D%3D 10.1093/annonc/mdl501 17298958
12. SS Lee JL Lee MH Ryu, et al. 2007 Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis Jpn J Clin Oncol 37 30 37 10.1093/jjco/hyl134 17272321
13. W Ichikawa Y Sasaki 2006 Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann Oncol 17 1665 1672 1:STN:280:DC%2BD28njtlKltA%3D%3D 10.1093/annonc/mdl174 16873435
14. S Fulda KM Debatin 2006 Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy Oncogene 25 4798 4811 1:CAS:528:DC%2BD28Xnsl2hsLc%3D 10.1038/sj.onc.1209608 16892092
15. JC Reed 2006 Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities Cell Death Differ 13 1378 1386 1:CAS:528:DC%2BD28XmvFaitb4%3D 10.1038/sj.cdd.4401975 16729025
16. ZH Siddik 2003 Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 7265 7279 1:CAS:528:DC%2BD3sXotlajtbY%3D 10.1038/sj.onc.1206933 14576837
17. E Reed 2005 ERCC1 and clinical resistance to platinum-based therapy Clin Cancer Res 11 6100 6102 1:CAS:528:DC%2BD2MXpslansrw%3D 10.1158/1078-0432.CCR-05- 1083 16144907
18. SY Kang JH Han KJ Lee, et al. 2007 Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy Clin Cancer Res 13 4146 4153 1:CAS:528: DC%2BD2sXnvVChsrk%3D 10.1158/1078-0432.CCR-06-3063 17634542
19. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 1:CAS:528:DC%2BD28XpsFKmtLw%3D 10.1056/NEJMoa060570 16957145
20. HW Lee JH Han JH Kim, et al. 2008 Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer Lung Cancer 59 95 104 10.1016/j.lungcan.2007.07.023 17889401
21. HM Pinedo GF Peters 1988 Fluorouracil: biochemistry and pharmacology J Clin Oncol 6 1653 1664 1:CAS:528:DyaL1MXotA%3D%3D 3049954
22. N Boku K Chin K Hosokawa, et al. 1998 Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum Clin Cancer Res 4 1469 1474 1:CAS:528: DyaK1cXktVWhsbo%3D 9626464
23. R Metzger CG Leishman KD Danenberg HJ Lenz K Hayashi S Groshen D Salonga H Cohen L Laine P Crookes H Silberman J Baranda B Konda L Leichman 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 309 316 1:CAS:528:DyaK1cXmsFeruw%3D%3D 9440758
24. HJ Lenz CG Leichman KD Danenberg, et al. 1996 Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J Clin Oncol 14 176 182 1:STN:280:DyaK287ktVaqtQ%3D%3D 8558194
25. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
26. E Kaplan P Meier 1958 Non-parametric estimations from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
27. DR Cox 1972 Regression model and life tables J R Stat Soc B 34 187 220
28. ZH Huang D Hua X Du, et al. 2008 ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer World J Gastroenterol 14 6401 6407 1:CAS:528:DC%2BD1MXis1eltbY%3D 10.3748/wjg.14.6401 19009659
29. HC Kwon MS Roh SY Oh, et al. 2007 Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Ann Oncol 18 504 509 10.1093/annonc/mdl430 17322540
30. J Wei Z Zou X Qian, et al. 2008 ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen Br J Cancer 98 1398 1402 1:CAS:528:DC%2BD1cXks12gu7w%3D 10.1038/sj.bjc.6604317 18362936
31. J Matsubara T Nishina Y Yamada, et al. 2008 Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer Br J Cancer 98 832 839 1:CAS:528:DC%2BD1cXitVGht7c%3D 10.1038/sj.bjc.6604211 18231104
32. PS Pinheiro LH van der Heijden JW Coebergh 1999 Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Lauren type and subsite Int J Cancer 84 28 32 1:STN:280:DyaK1M7ktVOhtQ%3D%3D 10.1002/(SICI)1097-0215(19990219) 84:1<28:AID-IJC6>3.0.CO;2-O 9988228
33. SY Kang YT Oh JH Han, et al. 2006 Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of Bax Neoplasma 53 450 456 1:CAS:528:DC%2BD28Xht12mtbjF 17013542